Compare IDEXX Laboratories, Inc. (IDXX) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs LTC Properties Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while LTC Properties Inc trades at $38.12 (market cap $2.05B). The key difference: IDEXX Laboratories, Inc. is far larger — about 22.5× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.98% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | LTC | |
|---|---|---|
Market Cap | $46.22B | $2.05B |
Sector | Health | Real Estate |
52-Week High | $766.68 | $42.81 |
52-Week Low | $526.44 | $33.98 |
Enterprise Value | $47.12B | $2.79B |
Dividend Yield | — | 5.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
LTC Properties (LTC) trades at $38.69, down 1.85% over 24 hours, with technical indicators showing a bearish trend despite oversold RSI readings. The company reported Q2 2026 earnings that beat expectations, with EPS of $0.56 versus $0.48 expected, and continues aggressive SHOP portfolio expansion, with recent acquisitions totaling over $285 million year-to-date. Revenue grew to $262.85 million in 2025, and net income margin remains strong at 38.93%, though recent quarters show mixed earnings performance.
LTC presents a mixed outlook; strong fundamentals and dividend yield near 5.9% appeal to income investors, but bearish technicals and elevated debt levels pose risks. Analyst consensus is cautious with 59% hold ratings, reflecting concerns over execution amid rapid portfolio growth. Key catalysts include SHOP acquisition success and demographic tailwinds, while risks involve interest rate sensitivity and integration challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
